Kaleido Rg-144A-Ai
Kaleido Biosciences, a clinical‑stage biotech, develops microbiome‑based metabolic therapies for urea cycle disorders, ulcerative colitis, hepatic encephalopathy, COVID‑19, and multi‑drug resistant infections backed by collaborations with Roussy, University, and Janssen.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 76
- HQ: Lexington
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.